We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
No events to show.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) The Globe and Mail
GlaxoSmithKline (GSK) Gets a Hold from UBS - The Globe and Mail
GlaxoSmithKline (GSK) Gets a Hold from UBS The Globe and Mail
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report? - Yahoo Finance
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report? Yahoo Finance
GSK : JP Morgan gives a Sell rating - marketscreener.com
GSK : JP Morgan gives a Sell rating marketscreener.com
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading - Proactive financial news
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading Proactive financial news
GSK’s hepatitis B drug touts functional curative potential in double Phase III win - Clinical Trials Arena
GSK’s hepatitis B drug touts functional curative potential in double Phase III win Clinical Trials Arena
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 28. | After market close (AMC) | — | — | — | $8.25B | — | Scheduled |
No research actions to show.
Price data
No holdings data to show.